(Q42271739)

19 October 2017

title

All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear). (English)

1 reference

19 October 2017

0 references

E J Lawitz

1

1 reference

19 October 2017

M Rodriguez-Torres

2

1 reference

19 October 2017

J Denning

3

1 reference

19 October 2017

A Mathias

4

1 reference

19 October 2017

H Mo

5

1 reference

19 October 2017

B Gao

6

1 reference

19 October 2017

M T Cornpropst

7

1 reference

19 October 2017

M M Berrey

8

1 reference

19 October 2017

W T Symonds

9

1 reference

19 October 2017

publication date

31 March 2013

1 reference

Journal of Viral Hepatitis

19 October 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

19 October 2017

volume

20

1 reference

19 October 2017

issue

10

1 reference

19 October 2017

page(s)

699-707

1 reference

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

19 October 2017

cites work

1 reference

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice

21 January 2018

1 reference

Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

21 January 2018

1 reference

Preliminary study of two antiviral agents for hepatitis C genotype 1.

21 January 2018

1 reference

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

21 January 2018

1 reference

Resistance to direct antiviral agents in patients with hepatitis C virus infection

21 January 2018

1 reference

Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus

21 January 2018

1 reference

Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA.

21 January 2018

1 reference

Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine

21 January 2018

1 reference

Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection

21 January 2018

1 reference

Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus

21 January 2018

1 reference

PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication

21 January 2018

1 reference

2'-deoxy-2'-α-fluoro-2'-β-C-methyl 3',5'-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: discovery of PSI-352938.

21 January 2018

1 reference

Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.

21 January 2018

1 reference

Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.

21 January 2018

1 reference

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JVH.12091

1 reference

19 October 2017

1 reference